Patents Assigned to BROAD INSTITUTE
  • Artificial transcription factors comprising a sliding domain and uses thereof
    Patent number: 10816547
    Abstract: The present invention relates to compositions which may comprise a non-naturally occurring or engineered artificial transcription factor, wherein the transcription factor may comprise a sequence specific DNA binding domain, a sliding domain, and one or more linkers, wherein the DNA binding domain and the sliding domain are operably connected by the one or more linkers, and uses thereof. Methods involving the use of a non-naturally occurring or engineered artificial transcription factors and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: October 27, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Paul Blainey, Anthony Kulesa, Kan Xiong
  • SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
    Publication number: 20200332272
    Abstract: The present disclosure provides methods for inhibiting intra and inter-cellular signaling pathways by modification of post-translation modification sites on select target RNA molecules. In certain example embodiments, the present disclosure provides methods for inhibiting intracellular phosphorylation of serine, threonine and tyrosine residues by editing the genetic codon of these amino acids by means of site-directed RNA editing or RNA molecules. Embodiments disclosed herein further provide methods of inhibiting pathological activation of cell signaling meditated by post-translational modifications, such as phosphorylation, which are involved in many diseases, including cancer, immunodeficiency, infectious diseases, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: October 23, 2018
    Publication date: October 22, 2020
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Mohammad Pirmoradian Najafabadi, Qiang Pan-Hammarström, Jonathan Gootenberg, David Benjamin Turitz Cox, Omar Abudayyeh
  • Systems and methods for culturing epithelial cells
    Patent number: 10801015
    Abstract: The present invention features assays for co-culturing primary cells while maintaining key biological activities specific to the primary cells. The invention is based, at least in part, on the discovery that compositions and methods for primary cells in a high-throughput co-culture platform, image analysis for distinguishing cells in co-cultures and assays that are suitable for screening of agents in epithelial cells, such as hepatocytes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 13, 2020
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Sangeeta Bhatia, Jing Shan, Anne Carpenter Van Dyk, David Logan, Nathan Ross
  • Compositions and methods for diagnosing, evaluating and treating cancer
    Patent number: 10801070
    Abstract: The present invention relates to methods of determining a cancer treatment prognosis for a subject in need thereof by evaluating epigenetic and genetic changes within a tumor sample from the subject. The present invention further provides methods of treating cancer in a subject by evaluating epigenetic and genetic changes within a tumor sample from the subject. In addition, the present invention provides methods of screening test agents to identify agents that decrease tumor cell plasticity.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: October 13, 2020
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Mark Kendell Clement, Gad Getz, Dan-Avi Landau, Alexander Meissner, Catherine Ju-Ying Wu
  • Nucleotide-specific recognition sequences for designer TAL effectors
    Patent number: 10801017
    Abstract: The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 13, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Le Cong, Sam Locascio
  • NOVEL CRISPR ENZYMES AND SYSTEMS
    Publication number: 20200318172
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng ZHANG, Bernd ZETSCHE, Johnathan S. GOOTENBERG, Omar O. ABUDAYYEH, Ian SLAYMAKER
  • CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
    Publication number: 20200318123
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Applicant: The Broad Institute, Inc.
    Inventor: Feng Zhang
  • NOVEL CRISPR ENZYMES AND SYSTEMS
    Publication number: 20200318173
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng ZHANG, Bernd ZETSCHE, Johnathan S. GOOTENBERG, Omar O. ABUDAYYEH, Ian SLAYMAKER
  • BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF
    Publication number: 20200317675
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 8, 2020
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. GRAY, Yanke LIANG, Hwan Geun CHOI, Thomas SUNDBERG, Alykhan SHAMJI, Ramnik XAVIER, David E. FISHER, Nisma MUJAHID
  • Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
    Patent number: 10793538
    Abstract: The present invention provides compounds of formula (I): or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 6, 2020
    Assignee: The Broad Institute, Inc.
    Inventors: Edward Holson, Fanny Lazzaro, David Olson, Florence Fevrier Wagner, Michel Weiwer
  • CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
    Publication number: 20200308604
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 1, 2020
    Applicants: EDITAS MEDICINE, INC., THE BROAD INSTITUTE INC., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng ZHANG, Deborah PALESTRANT, Beverly DAVIDSON, Jordi MATA-FINK, Edgardo RODRIGUEZ, Alexis BORISY
  • Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof
    Patent number: 10781444
    Abstract: The present invention generally relates to libraries, compositions, methods, applications, kits and screens used in functional genomics that focus on gene function in a cell and that may use vector systems and other aspects related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and components thereof. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 22, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Ophir Shalem, Neville Espi Sanjana, John Doench, David Root, Ella Nicole Biewener Hartenian
  • SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
    Publication number: 20200291382
    Abstract: The disclosure provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a RNA-targeting Cas13 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 17, 2020
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Jonathan Gootenberg, David Benjamin Turitz Cox, Omar Abudayyeh, Soumya Kannan
  • COMPOSITIONS AND METHODS FOR TREATING DISEASES
    Publication number: 20200291115
    Abstract: An engineered, non-naturally occurring molecule for target immunotherapy, comprising: (a) a first binding component capable of binding to a T cell; and (b) a second binding component capable of binding to a diseased cell.
    Type: Application
    Filed: March 16, 2020
    Publication date: September 17, 2020
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventor: Feng Zhang
  • SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING
    Publication number: 20200283755
    Abstract: The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 10, 2020
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, David Benjamin Turitz Cox, Jonathan Gootenberg, Omar O. Abudayyeh, Bernd Zetsche, Jonathan Strecker
  • NOVEL CRISPR ENZYMES AND SYSTEMS
    Publication number: 20200283743
    Abstract: In one aspect, embodiments disclosed herein are directed to engineered CRISPR-Cas effector proteins that comprise at least one modification compared to an unmodified CRISPR-Cas effector protein that enhances binding of the of the CRISPR complex to the binding site and/or alters editing preference as compared to wild type. In certain example embodiments, the CRISPR-Cas effector proteins a Type II effector protein. In certain other example embodiments, the Type V effector protein is Cas9 or an orthologs or engineered variant thereof. Example Cas9 proteins suitable for use in the embodiments disclosed herein are discussed in further detail below.
    Type: Application
    Filed: August 17, 2017
    Publication date: September 10, 2020
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng ZHANG, David Arthur SCOTT, Winston Xia YAN, Sourav CHOUDHURY, Matthias HEIDENREICH
  • COMPOSITIONS AND METHODS FOR LABELING OF AGENTS
    Publication number: 20200277596
    Abstract: The invention provides, inter alia, methods for uniquely labeling populations of agents of interest using random combinations of oligonucleotides. The oligonucleotides may comprise a unique nucleotide sequence and/or one or more non-nucleic acid detectable moieties.
    Type: Application
    Filed: February 18, 2020
    Publication date: September 3, 2020
    Applicant: The Broad Institute, Inc.
    Inventors: Scott Steelman, Robert Nicol, Robert E. Lintner
  • MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS
    Publication number: 20200277600
    Abstract: The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.
    Type: Application
    Filed: September 7, 2018
    Publication date: September 3, 2020
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Jonathan Gootenberg, Omar Abudayyeh
  • Dopamine D2 receptor ligands
    Patent number: 10752588
    Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 25, 2020
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier, Michel Weiwer, Edward Scolnick, Michelle Palmer, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
  • Compounds and methods for treating synovial sarcomas
    Patent number: 10752628
    Abstract: The present invention includes compound and methods that are useful in treating certain cancers, such as synovial sarcomas.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 25, 2020
    Assignees: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Cigall Kadoch, Enrique Garcia-Rivera, Micah Maetani, Stuart L. Schreiber